Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword

Alberto Pugliese

Several self-molecules have been identified as target antigens in autoimmune diseases. Since lack or loss of tolerance to these molecules is one of the key events promoting autoimmunity, researchers are exploring the possibility that the administration of antigens or peptides may stimulate tolerogenic mechanisms and delay or prevent the full phenotypic expression of autoimmune diseases. There is much enthusiasm for such therapies, as these will probably be disease-specific and not associated with the side effects of conventional immunosuppression. Studies have been performed and are ongoing in both rodents and humans, using whole antigens or peptides, and testing diverse administration routes such as intrathymic, intraperitoneal, intravenous, subcutaneous, oral, and intranasal. Despite many studies, robust data demonstrating clinical benefits are not yet available (1).

Antigen and/or peptide-based interventions in diabetes

Type 1 diabetes (T1D) represents one of the most suitable diseases to exemplify such heterogeneous outcomes. Three autoantigens — proinsulin/insulin, glutamic acid decarboxylase (GAD), and tyrosine phosphatase–like protein IA-2 (or ICA512) — have been identified as target antigens in autoimmune diabetes (2). Although all of these molecules are expressed in pancreatic islets, insulin and its precursor proinsulin are uniquely secreted by pancreatic β-cells. Several studies have suggested an important role for autoimmune responses to epitopes of insulin/proinsulin, such as the peptides B9–23 (the 9–23 amino acid region of the insulin B chain) (3, 4) and B24–C36 (the proinsulin B-chain–C-peptide junction) (5, 6). In NOD mice, both subcutaneous and oral administration of insulin can delay or prevent diabetes; oral insulin induces regulatory CD4+ T cells, while nasorespiratory insulin induces regulatory CD8+γδ-T cells (7–11). However, in a Diabetes Prevention Trial–Type 1 (DPT-1) study that involved the parental administration of insulin, no significant effect on progression to overt disease in autoantibody-positive first-degree relatives of T1D patients, who have increased risk of developing diabetes, was demonstrated (12). While the results of the oral insulin arm of DPT-1 are expected in June 2003, a randomized, crossover, pilot trial of intranasal insulin in at-risk first-degree relatives demonstrated changes in immune and metabolic markers that were consistent with an immunoprotective effect (13).

The subcutaneous or intranasal administration of the insulin peptide B9–23 can also prevent diabetes in NOD mice (3), similarly to the neonatal administration of the B10–24 peptide (9). However, the administration of several antigen-derived peptides, in addition to newborn NOD mice, resulted in the early activation of multiple autoimmune responses (14). Similarly, the intrathymic injection of T1D-associated antigens or peptides resulted in delayed or accelerated diabetogenesis, depending on the peptides used (15). Recent studies in mice have also shown that the repeated administration of insulin or GAD peptides, including the B9–23 peptide, can induce lethal ana phylactic responses (16, 17). While similar occurrences have not been reported in a phase I trial in which a modified insulin B9–23 peptide (altered peptide
ligand) was administered subcutaneously to normal individuals, the administration of any proinsulin or insulin peptides has not yet been attempted in the context of T1D prevention trials or in an attempt to halt autoimmunity in new onset patients. Clearly, more studies are needed as a number of factors, including the nature of the antigen or peptide, the dose, the route and/or mode of administration, and the stage of disease at which the subjects enter the trial, can all influence the efficacy and safety of these experimental treatments.

The double-edged sword

In the current issue of the JCI, Martinez et al. report on a new element that will need to be considered when attempting peptide-based T1D therapy (18). While the goal of peptide administration is to induce regulatory cells and inhibit specific autoimmune responses, the data show that, depending on the peptide used, one may also induce undesired cytotoxic CD8+ T cell responses. In this study, the intranasal administration of the B24–C36 proinsulin peptide to NOD mice induced regulatory cells that could transfer disease protection to another mouse, but the peptide-treated mice were not protected from developing spontaneous disease. The authors then noted that the B24–C36 peptide contains binding motifs not only for I-A\(^d\), the MHC class II molecule of the NOD mouse, but also for the MHC class I molecule K\(^d\). The B24–C36 peptide contains the B25–C34 and B26–C34 epitopes that bind to K\(^d\), and mice immunized with the latter two peptides mounted specific cytotoxic responses. In contrast, the systemic administration of B24–C34 reduced spontaneous diabetes incidence, confirming a role for CD8+ responses to this epitope in the natural disease process. Thus, intranasal administration of the B24–C36 peptide resulted in both regulatory CD4+ T cell and cytotoxic CD8+ T cell responses recognizing the K\(^d\)-restricted B25–C34 epitope contained in the B24–C36 peptide. Such cytotoxic responses blunted the protective effect associated with the induction of the regulatory cells, suggesting that mucosal administration of antigen can sometimes be a double-edged sword. To circumvent this problem, the authors designed a strategy to “disable” the CD8+ epitope contained in the B24–C36 peptide, in other words, to prevent CD8+ T cells from recognizing this epitope, while preserving the ability to induce regulatory CD4+ T cells (Figure 1 and Table 1). This was achieved by treating the mice with truncated peptides, B24–C33 or B24–C32, still capable of binding to I-A\(^d\) but not to K\(^d\). Intranasal administration of the truncated peptides resulted indeed in a significant reduction in the incidence of spontaneous diabetes.

The findings reported by Martinez et al. (18) suggest that the undetected induction of CD8+ T cell responses could explain at least some of the contrasting outcomes reported by several experimental studies and clinical trials. Most importantly, this study has practical implications for the design of clinical trials based on the administration of peptides for preventing autoimmunity. Based on these findings, it would seem helpful to select putative therapeutic peptides for their ability to selectively bind class II but not class I molecules that are used as restriction elements by CD8+ T cells and could potentially antagonize the beneficial effects of class II–restricted, regulatory CD4+ T cells. This strategy can effectively disable the potential of eliciting cytotoxic responses and maximize the protective effects of the regulatory cells. While this study was limited to the NOD mouse MHC molecules, the availability of mouse strains expressing human class II

<table>
<thead>
<tr>
<th>Proinsulin Peptides</th>
<th>I-A(^d)/K(^d) Binding</th>
<th>CD4+/'CD8' Responses</th>
</tr>
</thead>
<tbody>
<tr>
<td>B24-C36</td>
<td>Yes/Yes</td>
<td>Yes/Yes</td>
</tr>
<tr>
<td>B24-C33</td>
<td>Yes/No</td>
<td>Yes/No</td>
</tr>
<tr>
<td>B24-C32</td>
<td>Yes/No</td>
<td>Yes/No</td>
</tr>
</tbody>
</table>

Figure 1
Disabling a CD8+ epitope. Intranasal administration of different proinsulin peptides results in presentation from an antigen-presenting cell (APC) to CD4+ and CD8+ T cells, depending on the peptide administered. Proinsulin peptides B24–C36, B24–C35, and B26–C34 can bind to the MHC class I molecule (K\(^d\)), resulting in the activation of cytotoxic T cells. The use of truncated peptides that do not contain the residues critical for binding to K\(^d\), but still bind to the NOD mouse MHC class II molecule (I-A\(^d\)), allows for selective activation of regulatory CD4+ T cells. The same APC is shown presenting simultaneously to both CD4+ and CD8+ T cells for illustration purposes. TCR, T cell receptor.
Tissue glycogen content and glucose intolerance

Masato Kasuga, Wataru Ogawa, and Takeshi Ohara

Division of Diabetes and Digestive and Kidney Diseases, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan


Insulin stimulates glycogen synthesis in the liver and skeletal muscle. After a mixed meal, the secretion of insulin from pancreatic β cells thus results in about 20% and 30% of the carbohydrate intake being stored in the form of glycogen in the liver and skeletal muscle, respectively (1, 2). Defects in this process can therefore be a major contributor to postprandial hyperglycemia. Indeed, the glycogen contents of the liver and skeletal muscle are reduced in individuals with type 2 diabetes (3, 4).

Glycogen metabolism is controlled predominantly by the coordinated action of two enzymes, glycogen synthase and glycogen phosphorylase, both of which are regulated by phosphorylation and allosteric modulators. Insulin promotes the net dephosphorylation of both glycogen synthase and glycogen phosphorylase through the inhibition of protein kinases and the activation of protein phosphatases. Among the protein kinases, glycogen synthase kinase-3 (GSK-3) is thought to be an important target for insulin in its stimulation of glycogen synthase activity (5, 6). Among the protein phosphatases, protein phosphatase 1 (PP1) has been implicated in this action of insulin (6).

PP1 is an abundant protein serine-threonine phosphatase that is expressed in all compartments of eukaryotic cells. The catalytic subunit of PP1 thus interacts with a wide variety of targeting subunits that localize it to specific sites within the cell. A family of proteins that target PP1 to glycogen and thereby regulate its activity has been identified. These proteins include Gσ1 (PPP1R3), Gδ (PPP1R4), PTG (protein targeting to glycogen or PPP1R5), and PPP1R6.

Deletion of glycogen-targeting subunits of PP1 (PTG and Gσ1) in mice

PTG was cloned as a binding protein of the catalytic subunit of PP1 by Saltiel and coworkers in 1997 (7). This protein

The Journal of Clinical Investigation | May 2003 | Volume 111 | Number 9